Lijue Wang

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

14h-index605citations32works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(11), Ship Hydrodynamics and Maneuverability(8), COVID-19 Clinical Research Studies(7), SARS-CoV-2 detection and testing(6), Fluid Dynamics Simulations and Interactions(4)

Publications32 total

MERS-related coronavirus circulating in pangolins exhibits strong fusogenicity in human cells and high sensitivity to fusion inhibitors
Cell Reports Medicine·2025· 1 citedOpen Access
Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic recombinant EK1 peptide
Cell Discovery·2024· 13 citedOpen Access
Correction to: Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia
Clinical and Experimental Medicine·2023Open Access
Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia
Clinical and Experimental Medicine·2023· 4 cited
Repurposing Navitoclax to block SARS‐CoV‐2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein
Journal of Medical Virology·2023· 8 citedOpen Access
SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors
Journal of Medical Virology·2023· 19 citedOpen Access
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
Emerging Microbes & Infections·2023· 28 citedOpen Access
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Journal of Medical Virology·2022· 28 citedOpen Access
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Signal Transduction and Targeted Therapy·2022· 172 citedOpen Access
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
Viruses·2022· 19 citedOpen Access
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Cell Research·2022· 40 citedOpen Access
Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
Cell Discovery·2021· 24 citedOpen Access
25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses
International Journal of Molecular Sciences·2021· 21 citedOpen Access
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
Signal Transduction and Targeted Therapy·2021· 66 citedOpen Access
Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
Microbes and Infection·2021· 2 citedOpen Access
Construction and application of clinical trial management system
Zhongguo Linchuang Yaolixue Zazhi·2020
Strengthening the management of funds to improve the quality of drug clinical trials
Zhonghua yixue keyan guanli zazhi·2019
Heart Regeneration in Adult Mammals after Myocardial Damage.
PubMed·2018· 22 citedOpen Access
Analysis and countermeasures on defluxion cases in antihypertensive drug clinical trial
Zhonghua yixue keyan guanli zazhi·2016· 2 cited
Hydrodynamic Optimization of a Wedge Hull
2015· 17 cited
page 1 of 2Next →

Frequent Co-authors

Shuai Xia(13), Shibo Jiang(13), Fanke Jiao(12), Lu Lu(11), Wei Xu(8), Qian Wang(8), Chi Yang(8), Qiaoshuai Lan(7), Fuxin Huang(7), Yun Zhu(6), Jie Zhou(4), Fei Sun(3), Ziqi Huang(3), Zhenwei Xie(3), Chao Wang(2), Jasper Fuk‐Woo Chan(2), Kwok‐Yung Yuen(2), Xueying Yu(2), Xicheng Li(2), Qiuhong Man(2)